Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 10, Issue 2, Pages 273-279Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14712590903575620
Keywords
cytokines; immunotoxin; mAbs; naptumomab; NSCLC; pancreatic cancer; renal cell carcinoma; SEA; superantigen; T cell
Ask authors/readers for more resources
Importance of the field: New agents that specifically engage the immune system are being tested in a variety of malignancies. This review provides an overview of naptumomab, an immunotoxin, with encouraging clinical activity in Phase I trials. Areas covered in this review: This review examines the preclinical and the published clinical data with regards to naptumomab. What the reader will gain: This review provides the reader with an understanding of the mechanism of action, immunology, pharmacokinetics and clinical activity of this agent. Take home message: Naptumomab has a unique mechanism of action and appears to be an active agent in the treatment of refractory solid tumors such as renal cell carcinoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available